| dc.contributor.author | Mahesh, R. | |
| dc.date.accessioned | 2023-11-20T09:11:32Z | |
| dc.date.available | 2023-11-20T09:11:32Z | |
| dc.date.issued | 2014 | |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912791/ | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13186 | |
| dc.description.abstract | To investigate the anti-anxiety activity of “6k”, a novel 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist in in mice. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wolters Kluwer | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | 5-HT3 antagonist | en_US |
| dc.subject | Anxiety | en_US |
| dc.subject | Elevated plus maze (EPM) | en_US |
| dc.subject | Open field test (OFT) | en_US |
| dc.subject | Hole board test (HBT) | en_US |
| dc.title | Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||